These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30539877)

  • 81. Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.
    Liu Y; Hao X; Hu X; Li J; Wang Y; Wang H; Xing P; Li W; Ying J; Han X; Shi Y
    Thorac Cancer; 2018 Apr; 9(4):498-501. PubMed ID: 29411527
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan.
    Gemma A; Kusumoto M; Sakai F; Endo M; Kato T; Saito Y; Baba T; Sata M; Yamaguchi O; Yabuki Y; Nogi Y; Jinushi M; Sakamoto K; Sugeno M; Tamura R; Tokimoto T; Ohe Y
    J Thorac Oncol; 2020 Dec; 15(12):1893-1906. PubMed ID: 32927121
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    Gyawali B; West HJ
    J Clin Oncol; 2021 Jan; 39(3):175-177. PubMed ID: 33275490
    [No Abstract]   [Full Text] [Related]  

  • 84. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
    Fujimoto D; Tomii K; Otoshi T; Kawamura T; Tamai K; Takeshita J; Tanaka K; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Hata A; Tachikawa R; Otsuka K; Hamakawa H; Katakami N; Takahashi Y; Imai Y
    Lung Cancer; 2013 May; 80(2):159-64. PubMed ID: 23419507
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
    Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
    Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
    Wang S; Cang S; Liu D
    J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A Case of Osimertinib-Induced Eosinophilic Pneumonia.
    Patel KG; Corbett RL; Karanjawala ZE; Kelly KA; Stollenwerk N; Riess JW
    Clin Lung Cancer; 2022 Nov; 23(7):639-642. PubMed ID: 36104273
    [No Abstract]   [Full Text] [Related]  

  • 89. Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.
    Liu N; Yu M; Yin T; Jiang Y; Liao X; Tang J; Li Y; Qin D; Li D; Wang Y
    Signal Transduct Target Ther; 2020 May; 5(1):63. PubMed ID: 32457345
    [No Abstract]   [Full Text] [Related]  

  • 90. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
    Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
    J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
    [No Abstract]   [Full Text] [Related]  

  • 91. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
    Zhang S; Zhu L; Xia B; Chen E; Zhao Q; Zhang X; Chen X; Chen X; Ma S
    Cancer Commun (Lond); 2018 May; 38(1):28. PubMed ID: 29789021
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
    Yang X; Huang C; Chen R; Zhao J
    Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
    [No Abstract]   [Full Text] [Related]  

  • 94. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
    Chiang CL; Yeh YC; Chou TY; Chiu CH
    J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
    [No Abstract]   [Full Text] [Related]  

  • 96. ASTRIS: a global real-world study of osimertinib in >3000 patients with
    Marinis F; Wu YL; de Castro G; Chang GC; Chen YM; Cho BC; Freitas HC; Jiang L; Kim SW; Martin C; Metro G; Provencio M; Vansteenkiste J; Vicente D; Zhou Q; Miranda MF; Bakker NA; Rigas JR; Cheema PK
    Future Oncol; 2019 Sep; 15(26):3003-3014. PubMed ID: 31339357
    [No Abstract]   [Full Text] [Related]  

  • 97. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
    Finlay MR; Anderton M; Ashton S; Ballard P; Bethel PA; Box MR; Bradbury RH; Brown SJ; Butterworth S; Campbell A; Chorley C; Colclough N; Cross DA; Currie GS; Grist M; Hassall L; Hill GB; James D; James M; Kemmitt P; Klinowska T; Lamont G; Lamont SG; Martin N; McFarland HL; Mellor MJ; Orme JP; Perkins D; Perkins P; Richmond G; Smith P; Ward RA; Waring MJ; Whittaker D; Wells S; Wrigley GL
    J Med Chem; 2014 Oct; 57(20):8249-67. PubMed ID: 25271963
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.
    Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D
    J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042
    [No Abstract]   [Full Text] [Related]  

  • 99. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
    Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
    J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.